Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease.
Chagas disease is a neglected parasitic infection caused by the protozoan Trypanosoma cruzi (T. cruzi) that affects more than 6 million people, mainly in Latin America. Benznidazole is still the drug of choice in many countries to treat it in spite of its dosage regimen and adverse side effects such...
Main Authors: | Marcela S Rial, María L Scalise, Eva C Arrúa, Mónica I Esteva, Claudio J Salomon, Laura E Fichera |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-12-01
|
Series: | PLoS Neglected Tropical Diseases |
Online Access: | http://europepmc.org/articles/PMC5755931?pdf=render |
Similar Items
-
Benznidazole, itraconazole and their combination in the treatment of acute experimental Chagas disease in dogs
by: Eleonora Lima Alves Cunha, et al.
Published: (2019-01-01) -
Pharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a new formulation of benznidazole
by: Marisa Liliana Fernández, et al.
Published: (2016-03-01) -
Hepatic changes by benznidazole in a specific treatment for Chagas disease.
by: Tycha Bianca Sabaini Pavan, et al.
Published: (2018-01-01) -
Uneventful benznidazole treatment of acute Chagas disease during pregnancy: a case report
by: Valeria Rita Corrêa, et al.
Published: (2014-06-01) -
Treatment With Suboptimal Dose of Benznidazole Mitigates Immune Response Molecular Pathways in Mice With Chronic Chagas Cardiomyopathy
by: Priscila Silva Grijó Farani, et al.
Published: (2021-07-01)